Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda
Open Access
- 2 May 2017
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 1-7
Abstract
Hepatitis B (HBV) and C (HCV) are important causes of morbidity and mortality in people living with human immunodeficiency virus (HIV). The burden of these co-infections in sub-Saharan Africa is still unclear. We estimated the prevalence of the hepatitis B surface antigen (HBsAg) and hepatitis C antibody (HCVAb) among HIV-infected individuals in Rwanda and identified factors associated with infection. Between January 2016 and June 2016, we performed systematic screening for HBsAg and HCVAb among HIV-positive individuals enrolled at public and private HIV facilities across Rwanda. Results were analyzed to determine marker prevalence and variability by demographic factors. Overall, among 117,258 individuals tested, the prevalence of HBsAg and HCVAb was 4.3% (95% confidence interval [CI] (4.2–4.4) and 4.6% (95% CI 4.5–4.7) respectively; 182 (0.2%) HIV+ individuals were co-infected with HBsAg and HCVAb. Prevalence was higher in males (HBsAg, 5.4% [5.1–5.6] vs. 3.7% [3.5–3.8]; HCVAb, 5.0% [4.8–5.2] vs. 4.4% [4.3–4.6]) and increased with age; HCVAb prevalence was significantly higher in people aged ≥65 years (17.8% [16.4–19.2]). Prevalence varied geographically. HBV and HCV co-infections are common among HIV-infected individuals in Rwanda. It is important that viral hepatitis prevention and treatment activities are scaled-up to control further transmission and reduce the burden in this population. Particular efforts should be made to conduct targeted screening of males and the older population. Further assessment is required to determine rates of HBV and HCV chronicity among HIV-infected individuals and identify effective strategies to link individuals to care and treatment.Keywords
This publication has 33 references indexed in Scilit:
- Requirements for global elimination of hepatitis B: a modelling studyThe Lancet Infectious Diseases, 2016
- HIV-Infected or -Exposed Children Exhibit Lower Immunogenicity to Hepatitis B Vaccine in Yaoundé, Cameroon: An Appeal for Revised Policies in Tropical Settings?PLOS ONE, 2016
- Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2015
- A path to eradication of hepatitis C in low- and middle-income countriesAntiviral Research, 2015
- Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2015
- Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysisBMC Medicine, 2014
- Hepatitis C in Sub-Saharan Africa: Urgent Need for AttentionOpen Forum Infectious Diseases, 2014
- Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaborationThe Lancet, 2014
- Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/AIDSClinical Infectious Diseases, 2012
- Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical OutcomesJournal of Virology, 2009